Correction for Kovacs et al., “An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline”

Схожие документы

• An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
  по: Kovacs, Steven J., et al.
  Опубликовано: (2020)
• Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
  по: Sun, Haiying, et al.
  Опубликовано: (2016)
• Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of (14)C-Omadacycline in Rats
  по: Lin, Wen, et al.
  Опубликовано: (2016)
• Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
  по: Rodvold, Keith A, et al.
  Опубликовано: (2019)
• In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline
  по: Tanaka, S. Ken, et al.
  Опубликовано: (2016)